Yousif Capital Management LLC Sells 27,558 Shares of Pfizer Inc. (NYSE:PFE)

Yousif Capital Management LLC cut its position in Pfizer Inc. (NYSE:PFE) by 3.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 691,106 shares of the biopharmaceutical company’s stock after selling 27,558 shares during the quarter. Yousif Capital Management LLC’s holdings in Pfizer were worth $19,897,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in PFE. Wedge Capital Management L L P NC boosted its position in shares of Pfizer by 10.6% during the third quarter. Wedge Capital Management L L P NC now owns 10,865 shares of the biopharmaceutical company’s stock valued at $360,000 after buying an additional 1,044 shares during the last quarter. LMG Wealth Partners LLC boosted its holdings in shares of Pfizer by 11.7% during the 3rd quarter. LMG Wealth Partners LLC now owns 37,963 shares of the biopharmaceutical company’s stock valued at $1,259,000 after acquiring an additional 3,990 shares during the last quarter. Cardinal Capital Management boosted its holdings in shares of Pfizer by 4.1% during the 3rd quarter. Cardinal Capital Management now owns 30,329 shares of the biopharmaceutical company’s stock valued at $1,006,000 after acquiring an additional 1,185 shares during the last quarter. Bard Financial Services Inc. raised its holdings in shares of Pfizer by 9.7% during the third quarter. Bard Financial Services Inc. now owns 342,679 shares of the biopharmaceutical company’s stock valued at $11,367,000 after purchasing an additional 30,235 shares during the last quarter. Finally, MinichMacGregor Wealth Management LLC raised its holdings in shares of Pfizer by 29.5% during the third quarter. MinichMacGregor Wealth Management LLC now owns 7,961 shares of the biopharmaceutical company’s stock valued at $264,000 after purchasing an additional 1,815 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on PFE. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Finally, Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.06 during trading on Tuesday, hitting $26.32. The company had a trading volume of 24,286,365 shares, compared to its average volume of 42,105,117. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market capitalization of $149.04 billion, a P/E ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The stock has a 50 day simple moving average of $27.07 and a 200 day simple moving average of $28.52.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s revenue was down 41.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.14 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.